Endonovo Therapeutics (OTCQB: ENDV), an innovative biotechnology company, recently named Dr. Steven Levin, M.D., to its scientific advisory board. An article further discussing the appointment reads, “‘Dr. Levin’s vast experience with novel therapies in the anesthesiology and pain-management field, as well as his strong research interest to improve clinical practice in pain management, will be valuable scientific additions to Endonovo,’ Alan Collier, CEO of Endonovo Therapeutics, said in a news release (http://ibn.fm/UFbNO). ‘As a leader in the field of pain management, Steven will contribute valuable knowledge and expertise as we move our programs forward.’ . . . Levin’s membership in professional and scientific societies has included the American Society of Anesthesiology, the American Pain Society, the American Society of Regional Anesthesia, the Society in Anesthesia and the International Association for the Study of Pain. He is currently the co-chair of the Opioid Stewardship Clinical Community, as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System.”
To view the full article, visit http://ibn.fm/ss9O6
About Endonovo Therapeutics Inc.
Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable electroceuticals(TM) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable electroceuticals therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, postconcussion syndrome and multiple sclerosis. The company’s noninvasive electroceutical therapeutic device, SofPulse(R), using pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema, and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical stage electroceuticals therapeutic devices addresses chronic kidney disease, liver disease nonalcoholic steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”), and ischemic stroke. The company’s noninvasive, wearable electroceuticals therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php